Source: Eur Respir J, 58 (6) 2003969; 10.1183/13993003.03969-2020



Rating:

Share or cite this content

Citations should be made in the following way:
Markus Weckmann, Thomas Bahmer, Jannie Marie Sand, Sarah Rank Rønnow, Martin Pech, Cornelis Vermeulen, Alen Faiz, Diana Julie Leeming, Morten Asser Karsdal, Lars Lunding, Brian George G. Oliver, Michael Wegmann, Gudrun Ulrich-Merzenich, Uwe R. Juergens, Jannis Duhn, Yves Laumonnier, Olga Danov, Katherina Sewald, Ulrich Zissler, Marnix Jonker, Inke König, Gesine Hansen, Erika von Mutius, Oliver Fuchs, Anna-Maria Dittrich, Bianca Schaub, Christine Happle, Klaus F. Rabe, Maarten van de Berge, Janette Kay Burgess, Matthias Volkmar Kopp. COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy. Eur Respir J, 58 (6) 2003969; 10.1183/13993003.03969-2020

Member's Comments

No comment yet.

Related content which might interest you: PP115 – COL4A3 degradation predicts anti-IgE response in severe asthma Source: ERS Lung Science Conference 2021 Year: 2021 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007 The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001 Tryptase loss-of-function mutations reduce tryptase expression and predict asthmatic response to anti-IgE therapy Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018 A monoclonal antibody to IL-1B attenuates the late asthmatic response to antigen challenge in patients with mild asthma Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006 The airway inflammatory response in allergic mice is downregulated by budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 265s Year: 2001 Targeting atopic inflammation: anti-IgE treatment Source: Annual Congress 2007 - Novel therapies for severe asthma Year: 2007 Omalizumab, a novel therapy for severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma Source: Eur Respir J 2003; 21: 1046-1049 Year: 2003 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 An inhaled IGFBP-3 peptide attenuates steroid-resistant neutrophilic bronchial asthma through modulation of ER stress Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019 Changes in lung functions and inflammatory markers in induced sputum of patients with bronchial asthma and allergic rhinitis in relation to exposure to pollen allergens Source: Eur Respir J 2005; 26: Suppl. 49, 734s Year: 2005 Experimental specific immunotherapy with timpol decreases allergic sensitization and airway inflammation in murine model of bronchial asthma Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010